Real‐world data were collected to validate the prognostic value of the IPRPs model. The cohort included 39 adult patients with ACC (Table 3) from the FUSCC between 2013 and 2019, and tumour specimens were obtained with informed consent. Anti‐Ki67 (ab16667, Abcam, USA) anti‐fatty acid synthase (ab128870, Abcam, USA), anti‐fibronectin (ab2413, Abcam, USA), anti‐TSC1 (ab217328, Abcam, USA), and anti‐transferrin receptor (ab84036, Abcam, USA) antibodies were used to detect the abundance of the corresponding proteins by immunohistochemistry (IHC). Positive or negative staining of a certain protein in one FFPE slide was independently assessed by two experienced pathologists and determined as follows. The staining intensity level was graded from 0 to 3. Samples with no staining, weak, median and strong staining denote to the level of 0, 1, 2 and 3. Based on the coverage percentage of immunoreactive tumour cells (0%, 1‐25%, 26‐50%, 51‐75%, 76‐100%), the staining extent was ranging from 0 to 4. The overall IHC score grading from 0 to 12 was evaluated according to the multiply of the staining intensity and extent score. Negative staining represented grade 0 to 3 and positive staining from 4 to 12 for each sample. Risk score of each patient was calculated using the formula generated by the IPRPs model. The Kaplan‐Meier method was applied to validate the prognostic value of the model, and the median of the risk score was set as the cut‐off value.

Clinicopathological characteristics of 39 adult ACC patients (Fudan University Shanghai Cancer Center cohort)

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.